When acute myeloid leukemia returns after treatment or doesn’t respond to initial therapy, patients face a difficult challenge that requires new approaches to regain disease control and extend survival.

Understanding the Challenge of Returning Disease

When acute myeloid leukemia comes back after a period of remission, doctors call this a relapse or recurrent disease. This means the leukemia has returned after treatment appeared to work initially. In contrast, refractory acute myeloid leukemia describes a situation where the disease never fully responded to the first treatment attempt, meaning complete remission was never achieved because the chemotherapy drugs could not eliminate enough leukemia cells.^[3] Both situations require additional, often more intensive treatment strategies to bring the disease back under control.

The return of leukemia can happen at different times for different patients. Most relapses occur within the first two years after completing initial treatment. However, the risk of the disease coming back decreases as more time passes. After five years in remission, the chance of relapse becomes extremely small.^[13] The timing of relapse matters significantly because it influences what treatment options doctors might recommend and how likely those treatments are to work.

Several factors influence treatment decisions when acute myeloid leukemia returns or proves resistant. Doctors consider the patient’s age, overall health status, how long the disease stayed in remission during the first treatment, what treatments were used previously, and whether the leukemia has spread to other areas like the central nervous system.^[3] Understanding these factors helps the medical team design a treatment plan tailored to each individual’s situation.

Recognizing When the Disease Returns

Detecting a relapse involves watching for symptoms and conducting regular medical tests. Many of the symptoms that appear when acute myeloid leukemia returns mirror those experienced during the initial diagnosis. Patients might notice unusual bruising appearing without clear cause, swollen lymph nodes developing in the neck or other areas, persistent tiredness that doesn’t improve with rest, shortness of breath during normal activities, fever without an obvious infection, sweating heavily at night, persistent headaches, or bone pain that feels deep and achy.^[7]

However, these symptoms alone cannot confirm whether leukemia has returned, as many other conditions cause similar problems. To definitively determine if the disease has relapsed, doctors must perform specific medical tests. Blood tests examine samples taken from a vein to count the numbers of normal blood cells and leukemia cells present in the circulation. A bone marrow test removes a sample of marrow tissue, usually from the hip bone, to check how many leukemia cells remain in the bone marrow and to look for genetic changes in those cancer cells that might have developed since the initial diagnosis.^[7]

If doctors suspect the leukemia might have spread to the brain and spinal cord, they perform a lumbar puncture. This procedure uses a thin needle inserted into the lower back to collect a small amount of the fluid that surrounds the spinal cord. Laboratory technicians then examine this fluid for the presence of leukemia cells. In some cases, doctors also order a chest X-ray to look for enlarged lymph nodes in the chest area that might indicate disease spread.^[7]

Standard Chemotherapy Approaches for Relapsed Disease

Chemotherapy remains the primary treatment for relapsed or refractory acute myeloid leukemia. The specific drugs and combinations used depend on several factors, particularly how long the disease remained in remission after initial treatment. If the remission lasted longer than one year, doctors might recommend repeating cycles of the same or similar drugs used during the first treatment, sometimes at similar or higher doses.^[3]

One common approach involves repeating the 7-and-3 protocol. In this treatment schedule, patients receive cytarabine continuously for seven days while also receiving an anthracycline drug for three days. Anthracyclines are a class of chemotherapy drugs that work by interfering with the DNA inside cancer cells, preventing them from growing and dividing. The specific anthracycline used might be daunorubicin, doxorubicin, idarubicin, or mitoxantrone.^[3]

For patients whose disease returns more quickly or who didn’t respond to initial treatment, doctors often recommend different chemotherapy combinations that might work better in these circumstances. One option is the FLAG regimen, which combines fludarabine, cytarabine, and filgrastim. Filgrastim is a growth factor that helps the body produce more white blood cells, which can help protect against infections during treatment. Another combination called MEC uses mitoxantrone, etoposide, and cytarabine together.^[3]

Additional chemotherapy options include high-dose cytarabine combined with mitoxantrone, high-dose etoposide with cyclophosphamide, or a three-drug combination of cytarabine, daunorubicin, and etoposide. Some treatment plans use clofarabine and cytarabine with or without filgrastim.^[3] The choice among these options depends on the individual patient’s condition, previous treatments received, and how well their body can tolerate intensive chemotherapy.

Not all patients with relapsed or refractory acute myeloid leukemia are strong enough to receive intensive chemotherapy. Advanced age, other medical conditions, poor overall physical condition, or complications from previous treatments might make intensive therapy too risky. For these patients, doctors offer less intensive chemotherapy regimens that are easier on the body while still attempting to control the disease.

These gentler approaches might include azacitidine, which can be given alone or combined with venetoclax. Azacitidine belongs to a class of drugs called hypomethylating agents, which work by changing how genes in cancer cells are turned on or off, potentially causing the leukemia cells to mature normally or die. Similarly, decitabine represents another hypomethylating agent that can be used alone or with venetoclax. Some patients might receive clofarabine with or without cytarabine as a less intensive option.^[3]

Targeted Therapy for Specific Genetic Changes

Targeted therapy represents a newer approach that focuses on specific molecular characteristics of the leukemia cells. Unlike traditional chemotherapy that affects all rapidly dividing cells in the body, targeted therapy drugs are designed to attack specific proteins or genetic mutations found in cancer cells, potentially causing fewer side effects on normal, healthy cells.

For patients whose leukemia cells carry a mutation in the FLT3 gene, gilteritinib offers a targeted treatment option. FLT3 mutations occur in some acute myeloid leukemia cases and cause cells to grow and divide uncontrollably. Gilteritinib works by blocking the abnormal protein produced by the mutated FLT3 gene, helping to stop the cancer cells from multiplying. This medication has received approval from the U.S. Food and Drug Administration and the European Medicines Agency for treating relapsed or refractory acute myeloid leukemia with FLT3 mutations.^[11]

The approval of gilteritinib was based on clinical trial results showing that patients who received this targeted therapy experienced better outcomes compared to those who received standard salvage chemotherapy. The treatment proved well-tolerated by most patients, meaning side effects were generally manageable. This represents an important advance because it provides an effective option specifically for patients whose leukemia has this particular genetic characteristic.^[11]

Another targeted therapy option exists for patients whose leukemia cells carry mutations in genes called IDH1 or IDH2. These genes normally help cells process nutrients and energy, but when mutated, they produce abnormal proteins that contribute to leukemia development. For IDH1-mutated acute myeloid leukemia, ivosidenib provides a treatment that specifically blocks the abnormal IDH1 protein. For IDH2 mutations, enasidenib targets the abnormal IDH2 protein.^[11]

Both ivosidenib and enasidenib have shown encouraging results in clinical studies of relapsed or refractory disease, even in elderly patients and those who had received multiple previous treatments. Response rates of approximately 30 to 40 percent were observed, meaning these drugs successfully reduced leukemia cells in a significant portion of patients. Both medications have received approval from the U.S. Food and Drug Administration for relapsed or refractory acute myeloid leukemia with IDH1 or IDH2 mutations, though they have not yet received European Medicines Agency approval.^[11]

For patients whose leukemia cells express a protein marker called CD33 on their surface, gemtuzumab ozogamicin represents another targeted option. This drug is an antibody linked to a chemotherapy agent. The antibody portion recognizes and attaches to the CD33 protein on leukemia cells, delivering the chemotherapy directly to those cancer cells while largely sparing healthy cells that don’t have CD33 on their surface.^[3]

Stem Cell Transplantation as a Potentially Curative Approach

For patients who are physically fit enough and haven’t previously undergone the procedure, allogeneic hematopoietic stem cell transplantation represents the only established potentially curative therapy for acute myeloid leukemia. This treatment is often recommended after salvage chemotherapy successfully reduces the number of leukemia cells.^[2] The procedure involves first giving the patient high-dose chemotherapy to kill as many cancer cells as possible, then infusing healthy stem cells from a donor to replace the patient’s damaged blood-forming system.

For patients whose acute myeloid leukemia returns after they already received a stem cell transplant, the situation becomes more challenging. In these cases, if the patient maintains good physical condition and performance status, doctors might consider intensive therapy followed by cellular treatments such as donor lymphocyte infusion or even a second stem cell transplant. However, outcomes remain difficult, with fewer than 20 percent of these patients surviving five years after their second transplant.^[11]

Treatment When Leukemia Spreads to the Central Nervous System

Sometimes acute myeloid leukemia spreads beyond the blood and bone marrow to the central nervous system, which includes the brain and spinal cord. When this happens, patients need specialized treatment to reach leukemia cells in these protected areas. The blood-brain barrier, a natural protective mechanism, prevents many drugs in the bloodstream from entering the brain and spinal fluid, so doctors must deliver chemotherapy directly to where the leukemia cells are located.

This specialized treatment is called intrathecal chemotherapy. During the procedure, which is typically performed during a lumbar puncture, doctors inject chemotherapy drugs directly into the spinal fluid. The drugs most commonly used for intrathecal chemotherapy are methotrexate or cytarabine. Once injected into the spinal fluid, these drugs can circulate around the brain and spinal cord, reaching leukemia cells that have spread to these areas.^[3]

Promising Drugs Being Tested in Clinical Trials

Clinical trials represent an important option for patients with relapsed or refractory acute myeloid leukemia. These research studies test new treatments or new combinations of existing treatments to determine if they work better than current standard approaches. For patients whose disease hasn’t responded to standard therapies, clinical trials should be considered a first priority, as they may provide access to potentially effective new treatments not yet widely available.^[11]

One area of active investigation involves venetoclax combinations. Venetoclax is a drug that works by blocking a protein called BCL-2, which helps cancer cells survive when they should die. By blocking this protein, venetoclax can trigger leukemia cell death. Researchers are studying venetoclax combined with demethylating agents like azacitidine or decitabine, particularly for patients who haven’t received venetoclax during their initial treatment. These combinations have achieved encouraging response rates in clinical studies.^[3]

Clinical trials are also exploring venetoclax in combination with intensive salvage chemotherapy regimens to see if adding this targeted drug to traditional chemotherapy improves outcomes for patients with relapsed or refractory disease. These studies aim to determine the best ways to incorporate newer targeted therapies into treatment approaches.^[3]

The timing of relapse significantly influences treatment success, making it an important consideration in both standard care and clinical trial design. Patients who experience early relapse, meaning their disease returns within a short time after achieving remission, generally face more difficult challenges than those whose remission lasts longer before the disease returns. The genetic characteristics of the leukemia cells at relapse also matter greatly, as the cancer can evolve and develop new mutations over time.^[11]

Most Common Treatment Methods

• Intensive Chemotherapy Regimens
  • 7-and-3 protocol using cytarabine for seven days with an anthracycline (daunorubicin, doxorubicin, idarubicin, or mitoxantrone) for three days
  • FLAG regimen combining fludarabine, cytarabine, and filgrastim
  • MEC protocol using mitoxantrone, etoposide, and cytarabine
  • High-dose cytarabine with mitoxantrone
  • High-dose etoposide combined with cyclophosphamide
  • Triple combination of cytarabine, daunorubicin, and etoposide
  • Clofarabine and cytarabine with or without filgrastim
• Less Intensive Chemotherapy Options
  • Azacitidine alone or combined with venetoclax
  • Decitabine alone or with venetoclax
  • Clofarabine with or without cytarabine
• Targeted Therapy
  • Gilteritinib for FLT3-mutated acute myeloid leukemia
  • Ivosidenib for IDH1-mutated disease
  • Enasidenib for IDH2-mutated leukemia
  • Gemtuzumab ozogamicin for CD33-positive leukemia cells
• Stem Cell Transplantation
  • Allogeneic hematopoietic stem cell transplant following salvage chemotherapy
  • Donor lymphocyte infusion for post-transplant relapse
  • Second stem cell transplant in selected cases
• Central Nervous System Treatment
  • Intrathecal chemotherapy with methotrexate or cytarabine delivered directly into spinal fluid

Factors Influencing Treatment Selection and Success

The prognosis for patients with relapsed acute myeloid leukemia depends largely on two main factors: when the relapse occurs and whether allogeneic hematopoietic stem cell transplantation remains possible. Early relapses, occurring soon after initial treatment, generally indicate more aggressive disease that may be harder to control with subsequent therapies. In contrast, late relapses that occur after extended periods of remission often respond better to additional treatment.^[11]

The ability to proceed to stem cell transplantation makes a significant difference in long-term outcomes. For fit patients who haven’t previously undergone transplant, the goal of salvage therapy is to reduce the leukemia burden enough to make transplantation possible. This potentially curative approach offers the best chance for long-term disease control and survival.^[11]

For patients who are not candidates for intensive therapy due to age, other health conditions, or poor physical status following previous treatments, the therapeutic goal shifts. Rather than pursuing aggressive disease elimination, treatment focuses on prolonging life while maintaining acceptable quality of life. Less intensive options become more appropriate, including hypomethylating agents, low-dose cytarabine, or sometimes just supportive therapy with hydroxyurea to control blood cell counts.^[11]

Managing Side Effects and Supporting the Body During Treatment

Treatment for relapsed or refractory acute myeloid leukemia often causes side effects that require management. These can include severe drops in blood cell counts, increasing vulnerability to infections, bleeding problems, fatigue, nausea, loss of appetite, and damage to various organs. The intensity and type of side effects depend on which treatments are used and how the individual patient responds.

Intensive chemotherapy regimens typically cause more severe side effects than less intensive approaches. Patients receiving intensive salvage therapy often require hospitalization so medical teams can closely monitor blood counts, provide supportive care including blood product transfusions, and quickly treat any infections that develop. The chemotherapy temporarily damages the bone marrow’s ability to produce blood cells, causing periods of very low white blood cell counts that leave patients vulnerable to serious infections.

Targeted therapies generally cause fewer side effects than traditional chemotherapy because they specifically attack cancer cells rather than affecting all rapidly dividing cells. However, they still produce side effects related to their specific mechanisms of action. For example, drugs targeting IDH mutations can sometimes cause a condition called differentiation syndrome, where too many white blood cells mature at once, causing symptoms like fever, breathing difficulties, and fluid retention. This condition requires prompt recognition and treatment with corticosteroids.

The Role of Supportive and Palliative Care

Supportive care plays a crucial role throughout treatment for relapsed or refractory acute myeloid leukemia. This care focuses on managing symptoms, preventing complications, and maintaining quality of life regardless of whether disease-directed treatment continues. Supportive measures include blood transfusions to treat anemia, platelet transfusions to prevent bleeding, antibiotics and antifungal medications to prevent and treat infections, and medications to control pain, nausea, and other symptoms.

Emerging evidence demonstrates that early integration of palliative care with standard leukemia treatment results in improved quality of life, better psychological outcomes, and greater participation in advance care planning for patients with acute myeloid leukemia.^[16] Palliative care specialists work alongside hematologists to address the full range of physical, emotional, and practical challenges that patients and families face.

The illness trajectory in acute myeloid leukemia differs from many solid tumor cancers, creating unique challenges for palliative care planning. The disease can rapidly deteriorate or unexpectedly improve, making prognosis particularly uncertain. This unpredictability affects decisions about when to transition from active treatment to comfort-focused care, when to consider hospice enrollment, and how to balance treatment-related burdens against potential benefits.^[16]

Looking Forward: Research Directions and Hope

Despite the challenges, ongoing research continues to develop new treatment approaches for relapsed and refractory acute myeloid leukemia. Scientists are investigating additional targeted therapies that attack different molecular vulnerabilities in leukemia cells. Immunotherapy approaches that harness the immune system to fight cancer are being explored, though these remain largely experimental in acute myeloid leukemia compared to their success in other cancers.

Researchers are also working to better understand why some patients’ leukemia cells develop resistance to treatment. By identifying the mechanisms that allow cancer cells to survive therapy, scientists hope to develop strategies to overcome resistance or prevent it from developing in the first place. This includes studying how leukemia cells evolve genetically over time and identifying new genetic mutations that emerge at relapse.

The development of less toxic but still effective treatments remains a priority, particularly for elderly patients and those with other health conditions who cannot tolerate intensive therapy. Finding ways to achieve disease control while preserving quality of life represents an important goal that could benefit many patients with relapsed or refractory disease.